Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

AUTOR(ES)

Ballard, Clive

FONTE

BMJ Publishing Group Ltd.

RESUMO

Objectives To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance.

Documentos Relacionados

• Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial
• A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.
• Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
• Randomised, double blind, placebo‐controlled trial of selenium supplementation in adult asthma